Introduction
Congenital bilateral absence of vas deferens (CBAVD) occurs in 1-2% of infertile but otherwise healthy men (Holsclaw et al., 1971) . It also accounts for as much as 25% of infertile males with obstructive azoospermia (Patrizio and Salameh, 1998) . CBAVD is present in more than 95% of cystic fibrosis (CF) males. Different studies have shown a high frequency of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in CBAVD patients (Costes et al., 1995; Dork et al., 1997; Mak et al., 1999; Casals et al., 2000; Dayangac et al., 2004; Grangeia et al., 2004) . In intron 8 of the CFTR gene, the T5 allele, in contrast with the other two alleles, T7 and T9, leads to a high proportion of mRNA transcripts lacking exon 9. Consequently, the T5 variant produces abnormally low levels of CFTR protein. The T5 variant is the most frequent mutation associated with the CBAVD phenotype .
Low frequencies of CFTR mutations have been detected in patients with unilateral absence of vas deferens (CUAVD) Mickle et al., 1995) . Between 11 and 26% of patients with congenital absence of vas deferens (CAVD) have renal agenesis in association with it (Schlegel et al., 1996) , and initial negative results in the analysis of CFTR mutations in these patients suggested that urogenital anomalies have a different etiology to isolated CAVD (Augarten et al., 1994) .
Little is known about the spectrum and frequency of CFTR gene mutations in India. Our recent study as well as few other investigations have provided evidence for an extensive allelic heterogeneity in Indian patients with classic CF (Sharma et al., 2009; Shastri et al., 2008) . Congential absence of vas deferens, as a distinct clinical entity with regard to CFTR mutations, has never been investigated in our population. We recently investigated the family history of infertility among CF subjects and characterized mutations in infertile members (Sharma et al., 2008) . We here report the detailed investigation of CFTR mutation genotypes in 50 Indian CAVD patients. We have identified CFTR gene alterations that are distinct from other populations.
Materials and Methods

Patients and clinical evaluation
A total of 50 consecutive men with a diagnosis of CAVD were studied. Healthy subjects (n ¼ 50) with no signs and symptoms of disease served as controls. All samples were representative of the Indian population. None of the men had been diagnosed with CF (Welsh and Smith, 1995) . In all cases, the initial evaluation included a scrotal examination and a semen analysis. Overall, CBAVD was found in 40 men, while 10 men had CUAVD which affected either the right (n ¼ 6) or left (n ¼ 4) side. Complete clinical data concerning infertility were obtained. The diagnosis of CAVD was based on physical examination, when one or both vasa deferentia were non-palpable in the scrotal portion. Semen analysis included volume, pH, sperm count and motility, in accordance with WHO guidelines (World Health Organization, 1999) . Concentration of fructose was measured with commercial kits (FructoScreen, New York, NY, USA). Hormone assays were done by chemiluminescence. Transrectal ultrasonography was performed for the morphology and size of the seminal vesicles, prostate and ejaculatory ducts. Abdominal ultrasonography was performed in order to evaluate the pelvis and the upper urinary tract. Testicular fine needle aspiration cytology (FNAC) was carried out for studying the patterns of spermatogenesis. Sweat chloride analysis was performed in all the subjects (Gibson and Cooke, 1959) . None of the patient had a family history of CF, and only patients who were apparently unrelated were included in this study. Classic lung and gastrointestinal symptoms of CF were not documented in any of the subjects. Of the 50 subjects, 40 individuals had consulted for couple infertility. Female partners (n ¼ 40) of these infertile subjects were analyzed only for the most common F508del mutation.
CFTR gene analysis
The study was approved by Institutional Ethics Committee in the Post Graduate Institute of Medical Education and Research, Chandigarh. DNA analyses were performed after written informed consent. Genomic DNA was isolated from whole blood following the method of Daly et al. (1996) .
For CFTR mutation analysis, chromosomes were first screened for the presence of the F508del by ARMS PCR as described by Ferrie et al. (1992) . We next screened R117H, N1303K and R553X each by single ARMS PCR and 621 þ 1G-T, G542X, G551D and W1282X by multiplex ARMS PCR.
CFTR mutations investigated by restriction analysis of PCR products were R334W (MspI), R347P (NcoI), A455E (AciI), 2789 þ 5 . G-A (SspI), R1162X (DdeI) and 3849 þ 10 kb . C-T (HphI) as described previously (Dean et al., 1990; Highsmith et al., 1990; Kerem et al., 1990; Gasparini et al., 1991a, b) .
The T5 variant in the polymorphic region IVS8-6(T) was analyzed as described previously . Bidirectional sequencing (Applied Biosystems) of intron 8 of the CFTR gene was carried out to determine TG repeat number and phase of TG-T repeat combinations.
The presence of mutations in the 27 exons and exon-intron boundaries of the CFTR gene were assessed by single-strand conformational polymorphism (SSCP) (Orita et al., 1989) . To avoid the overestimation of the pathological significance of the identified novel sequence variants, we used normal controls in each run to prevent over interpretation of SSCP patterns as abnormal. The patients' samples exhibiting shifts relative to normal samples on SSCP were subjected to automated DNA sequencing with forward and reverse primers, using an ABI Prism BigDye Terminator Sequencing Ready Reaction Kit (Perkin Elmer, USA) and a DNA sequencer ABI Prism (Model 3100, Perkin Elmer). Nucleotide numbering was based on the A of the ATG translation start codon at position þ133 (GenBank NM-000492.2).
Detection of intragenic markers for haplotype framework
The polymorphic markers, TUB9 (Dork et al., 1992) , M470V and T854T (Kerem et al., 1990) , were determined by restriction digests of RFLP-PCR. The GATT polymorphism (Gasparini et al., 1991a, b) was detected by the difference in mobility of the PCR product on 12% polyacrylamide gels. Haplotypes were assigned according to the standard nomenclature. The absence of the restriction site for each enzyme was indicated as allele 1 and the presence of the site as allele 2. For GATT polymorphism, alleles 1 and 2 denoted for seven and six GATT repeats, respectively (Dork et al., 1992) .
Results
Overall mutations identified
A total of 12 mutations were identified on 48 of 100 alleles, as listed in Table I . Two mutations were found to be very common: first, the IVS8-T5 allele was observed on 25 chromosomes; thus confirming the association of this splice site variant with CAVD in Indian patients. Secondly, the F508del mutation was detected in 11 chromosomes. In the CAVD patients with normal renal development, the initial screening identified one extra, R117H mutation in three chromosomes. SSCP analysis performed in patients with only one or no mutation revealed nine further mutations on one allele each including seven new sequence alterations: L69H, F87I, G126S, F157C, E543A, Y852F and D1270E (Table I) . Other identified mutations R117H, 3120 þ 1 . G-A and P1021S have been described previously in studies of patients with CAVD. None of the other screened mutations were identified in our population.
Pathological predictions and multiple sequence alignments of novel substitution mutations
The output prediction scores (http://blocks.fhrc.org/sift/SIFT.html) for L69H, E543A and D1270E were less than the 0.05 (threshold for pathological mutations) (Table II) . Pathological predictions confirmed by another computer algorithm (http://genetics.bwh.harvard.edu/pph) revealed L69H, E543 and D1270E as deleterious mutations and other four mutations, F87I, G126S, F157C and Y852F, as benign sequence alterations (Table II) . Human splicing finder matrices (http://www. umd.be/HSF/HSF.html) predicted no difference in splicing between the novel mutants and their respective wild-type reference sequences (Table II) . Multiple sequence alignment using ClustalW (http://align. genome.jp/) confirmed that the wild-type form of all the novel sequence variants, except F87I, was conserved across human, rhesus monkey, bovine, sheep, horse, dog, pig, rabbit and mouse ( Fig. 1 ).
Genotype and haplotype framework of Indian CAVD patients
Two allelic mutations were identified in 11 (22%) cases of which 5 were homozygous for IVS8-T5 (Table III) . Monoallelic mutations were found in 26 (52%) cases. We failed to identify mutations in either allele in 13 (26%) cases. Since the disease penetrance of T5 is affected by its adjacent polymorphic TG repeats, it was found that T5 on one or both alleles (n ¼ 25) was associated with either (TG)11 (n ¼ 4), (TG)12 (n ¼ 14) or (TG)13 (n ¼ 7). F508del was mostly found in patients carrying the (TG)10T9 haplotype. Rare or undescribed haplotypes (TG)13T9 (n ¼ 1) or (TG)13T7 (n ¼ 1) were also identified in Indian CAVD chromosomes. Haplotype studies including (GATT) n , TUB9, M470V and T854T were not found relevant for identified CFTR mutations, except for F508del. The most common intragenic marker haplotype for F508del was 2111 (72.27%), with the order of polymorphism being (GATT) n , TUB9, M470V and T854T (Table III) .
T5 and T9 alleles were significantly more frequent in the chromosomes of the patients with CBAVD (26 and 31%, respectively) and CUAD (20 and 45%, respectively) compared with control subjects (5 and 5%, respectively) (Table IV) . Further, (TG)12 was frequent in both CBAVD (46%) and CUAD (45%). However, (TG)11 was predominant in control subjects (68%). (TG)10 and (TG)13 were rare (1%) in control subjects in contrast to CBAVD and CUAD patients where its frequency was more than 10% (Table IV) .
Clinical phenotype
Of 50 patients with CAVD, 40 had CBAVD and 10 had CUAVD (Table V) . Unilateral renal agenesis was found in one CBAVD and three CUAVD subjects. Both CBAVD and CUAVD patients with the absence of kidney presented no CFTR mutations. Unilateral absence of seminal vesicles (n ¼ 5) typically on the same side of the absent vas deferens predominated in CUAVD, whereas bilateral dysplasia (n ¼ 2) was found only in CBAVD (Table V) . There were no associations between the mutations detected and biochemical variables studied (data not shown). However, median sweat chloride was higher in CBAVD compared with CUAVD subjects. Further, semen volume, pH, fructose and citrate contents were significantly lower (P , 0.05) in CBAVD compared with CUAVD subjects (Table V) . None of the patients showed pulmonary or gastrointestinal symptoms of CF, but repeated respiratory infections or bronchitis and raised sweat chloride were documented in a CBAVD patient with F508del/G126S genotype. A compound heterozygous, R117H/F87I, genotype was identified in a CBAVD subject with normal sweat chloride and no CF-like symptoms. 
Discussion
In Indian infertile men with CAVD, the initial screening for the most common CFTR mutations led to the identification of 39% alleles. Further, SSCP analysis detected 9% of the CAVD alleles with at least one CFTR mutation detected (Table I ). The present report is of one of the lowest frequencies of CFTR mutations in comparison with most other countries (71 -82%), such as the USA (Oates and Amos, 1994) , Germany (Dork et al., 1997) , France (Claustres et al., 2000) , Greece (Kanavakis et al., 1998) and Spain (Casals et al., 2000) . SSCP is simple and easy to set up, but its sensitivity depends on PCR fragment size. More than 90% of the sequence variations can be detected for most fragments shorter than 200 nucleotides, but about 80% for 300 -350 nucleotides PCR fragments (Hayashi and Yandell, 1993) . In the present study, the primers generated PCR products mostly above 250 base pairs which may have contributed to the decreased number of mutations detected. Sensitivity is also dependent on electrophoretic conditions such as temperature, ionic strength, composition of the gel and glycerol concentration. Previously, we standardized all parameters for each CFTR exon to optimize the sensitivity of SSCP (Sharma et al., 2009) . Failure to detect mutations in about 50% of CAVD alleles could be indeed due to the presence of other defects in introns or the promoter region of CFTR, but also to the presence of large rearrangements such as exon deletions, insertions or duplications, which have already been found in CBAVD patients (Hantash et al., 2006; Ratbi et al., 2007; Taulan et al., 2007) .
Intriguingly, among the seven novel substitution mutations identified, L69H, E543A and D1270E were predicted to be damaging, whereas F87I, G126S, F157C and Y852F were possibly neutral (http://blocks.fhcrc.org/sift/SIFT.html and http://genetics.bwh. harvard.edu/pph/). It is noteworthy that L69H has been previously identified on one allele of the Indian classic CF patient (Sharma et al., 2009) . The consequences of exonic alterations are not necessarily restricted to the protein level that is the subject of the SIFT and polyphen programmes used. Some variants may already be operational at the transcript level. But, the evaluation of potential effect on splicing (http://www.umd.be/HSF/HSF.html) predicted that none of these novel substitution mutations have an effect on splicing. Missense mutations of conserved sequences have been reported to have pathological significance in CBAVD patients (Grangeia et al., 2008) . Since F87I mutation is not conserved across various species (http://align.genome.jp/), it implies that it is a rare neutral sequence variation rather than a disease-causing mutation. Other novel mutations (G126S, F157C and Y852F) have been identified as possibly neutral, but are aligned across different species. Furthermore, these mutations have not been identified in the Indian classic CF patients (Sharma et al., 2009; Shastri et al., 2008) , and not finding a specific variant in the 100 normal chromosomes tested indicates that the variant has a frequency of ,5% (Collins and Schwartz, 2002) . Nevertheless, further functional studies are required for their pathological significance.
In CBAVD patients, a high frequency of compound heterozygosity with severe/mild or mild/mild mutations has been reported Figure 1 Multiple alignments of CFTR amino acid sequences from different species (human, rhesus monkey, bovine, sheep, pig and mouse) and seven novel substitution mutations (L69H, F87I, G126S, F157C, E543A, Y852A and D1270E) identified in Indian CAVD patients. Amino acids in box indicate alignment across different species. Full-length CFTR sequences of different species were obtained from UCSC genome browser (http://genome.ucsc.edu/). (Anguiano et al., 1992) . In the Indian CBAVD population, F508del mutation was 11%, an allelic frequency similar (12 -14%) to Greece (Kanavakis et al., 1998) and Portugal (Grangeia et al., 2004) , but lower than that found (21-33%) in Canada (Jarvi et al., 1998) , USA (Oates and Amos, 1994) , Germany (Dork et al., 1997) , France (Claustres et al., 2000) and Spain (Casals et al., 2000) . In the Indian CBAVD population, 74% of the patients had at least one CFTR or T5 mutation; 22% had two mutations and 52% had only one mutation, whereas 26% had no mutation detected (Table III) .
In CBAVD patients, one of the most frequent genotypes found is the combination of the T5 allele with other CFTR exonic mutations . This suggests that the vas deferens is the most susceptible tissues to the effect of the changes in CFTR activity (Anguiano et al., 1992) . In Indian CAVD patients, there were 40% of cases with T5 allele (Table III) , having an allele frequency of 25%. A (TG)12T5 or (TG)13T5 CFTR gene found in compound heterozygosity with a CF-causing mutation, or possibly even in homozygosity, in general results in CAVD (Castellani et al., 2008) . From a genetic diagnostic standpoint, CFTR mutations have been divided into (i) CF-causing disorder; (ii) CFTR-related disorder; (iii) no clinical consequence and (iv) unproven clinical relevance (Dequeker et al., 2009) . In the present study, the absence of vas deferens as CFTR-related disorder was confirmed in cases with one CFTR mutation and T5 allele associated with (TG)12 or (TG)13 (Table III) No mutation detected 26%
The IVS8-(TG) m T n haplotypes were named by the number of upstream TG dinucleotides followed by the number of consecutive thymidines (Groman et al., 2004) . The TUB9, M470V and T854T were designated as 1 for the absence and 2 for the presence of restriction site (Dork et al., 1992) . Alleles 1 and 2 denoted for seven and six GATT repeats, respectively. ? denotes unknown mutation.
confirmed in cases with 0 -1 CFTR mutation or T5. Since family studies have not been performed, it cannot be precisely determined at this point whether patients carrying two CFTR mutations are true compound heterozygotes, especially in cases where novel mutations could be in cis with the T5 (Table III) . The presence of mutation on more than one haplotype background in a particular geographical region indicates a longer history of the mutation that has allowed recombination events (Raskin et al., 1997) . The linkage disequilibrium data between CF and the dimorphic extragenic B haplotypes (1/2, XV2c-KM19) in different European populations are compatible with a relatively more recent appearance of the mutation in Northern Europe, whereas in Southern Europe a longer history of the same mutation would have allowed time for recombination with other haplotypes (Claustres et al., 1996) . In corroboration, we observed 2111 as the most common intragenic marker haplotype for F508del, the order of four intragenic polymorphic sites being GATT, TUB9, M470V and T854T (six GATT repeats, nucleotide G at TUB9 and M470V, and nucleotide T at T854T). Thus, we predict a more recent appearance of delta F508 in India. Haplotype studies were not found relevant for other identified CFTR mutations. Further studies demand investigation into the selection of these mutations in our population. In the present series, one couple showed F508del mutation on either allele (data not shown). It confirms previous reports (Kapoor et al., 2006; Sharma et al., 2008 Sharma et al., , 2009 ) that carrier frequency is expected to be high among Indians. Proper counseling was given to the couple of having a 25% chance of giving birth to a full blown CF child, if entering assisted reproduction techniques. Genetic counseling is especially difficult in CAVD subjects having a severe allele (F508del) on one loci and the other allele being uncharacterized or having a sequence variant with unknown pathological significance. There was no correlation between the CFTR mutation and development of either unilateral or bilateral vas deferens (Table V) . It leads us to assume that it is not just the CFTR mutations per se but there are certain modifiers genes or environment that collectively determines the clinical phenotype. Although, we and other investigators (Anguiano et al., 1992; Augarten et al., 1994) did not find any CFTR mutations in CAVD subjects with renal agenesis, Casals et al. (2000) reported that about one-third of the patients with CAVD and renal agenesis had CFTR mutations. We attribute this conflicting results to the reduced number of samples in our and previous studies compared with the latter report. It is suggested that studying genome-wide data substantiated with complete analysis of CFTR can provide convincing correlation and better counseling of the patients.
Taken together, we have characterized the type and frequency of CFTR mutations and of IVS8 poly (T) variants in Indian CAVD males with the absence of CF clinical symptoms. Identification of 7 novel mutations out of 12 reflects the molecular heterogeneity of CFTR mutations in CAVD and emphasizes the importance of extensive CFTR analysis in Indian population. The study also demands further investigation into the functional aspects of novel variants in the cell-based system to predict their pathological significance.
